One-liner#

Chronic coronary syndrome (stable CAD) requires lifelong secondary prevention to reduce cardiovascular events, antianginal therapy for symptom control, and risk stratification to identify patients who benefit from revascularization.

Quick nav#

• Definition and epidemiology
• Pathophysiology
• Clinical presentation
• Diagnostic workup
• Treatment
• Patient education
• Prognosis and monitoring
• Special populations
• When to refer
• Smartphrase snippets
• Related pages

Definition and epidemiology#

Diagnostic criteria#

Chronic coronary syndrome (CCS) encompasses stable manifestations of CAD including:

• Stable angina pectoris: predictable exertional chest discomfort relieved by rest or NTG
• Ischemic cardiomyopathy: LV dysfunction due to CAD
• Post-ACS stabilization: >12 months after acute event
• Post-revascularization: stable after PCI or CABG
• Asymptomatic CAD: documented disease without symptoms

Diagnosis requires either:

1. Documented obstructive CAD (≥50% stenosis on angiography or CCTA), OR
2. Evidence of ischemia on functional testing (stress ECG, stress imaging), OR
3. Prior MI, PCI, or CABG

Epidemiology#

• Prevalence: ~20 million adults in US; leading cause of death worldwide
• Risk factors: HTN, dyslipidemia, diabetes, smoking, family history of premature CAD (male <55, female <65), obesity, sedentary lifestyle
• Annual mortality: ~2-3% for stable CAD on optimal medical therapy; higher with reduced EF or extensive disease
• Sex differences: Women present ~10 years later than men; more likely to have microvascular disease and atypical symptoms

Pathophysiology#

Mechanism (clinical understanding)#

Atherosclerosis progression:

1. Endothelial dysfunction from risk factors (HTN, smoking, hyperglycemia, dyslipidemia)
2. LDL infiltration into arterial wall → oxidation → inflammatory response
3. Macrophage uptake of oxidized LDL → foam cells → fatty streak
4. Smooth muscle migration and proliferation → fibrous cap formation
5. Plaque growth → progressive luminal narrowing

Plaque stability determines clinical presentation:

• Stable plaques: thick fibrous cap, small lipid core, calcified → cause stable angina through fixed stenosis
• Vulnerable plaques: thin fibrous cap, large lipid core, inflammatory cells → prone to rupture → ACS

Supply-demand mismatch:

• Fixed stenosis >70% limits coronary flow reserve
• At rest: adequate perfusion despite stenosis
• With exertion: increased myocardial oxygen demand exceeds supply → ischemia → angina
• This explains why symptoms are predictable and reproducible with similar exertion levels

Why secondary prevention works:

• Statins: stabilize plaques (reduce lipid core, thicken fibrous cap, reduce inflammation)
• Aspirin: prevents platelet aggregation at sites of plaque erosion
• ACE-I/ARB: reduce vascular remodeling, improve endothelial function
• Beta-blockers: reduce myocardial oxygen demand, may reduce plaque stress

How to explain to patients#

“Your heart arteries have a buildup of cholesterol and scar tissue called plaque—like rust building up inside a pipe. When the buildup gets significant, your heart muscle doesn’t get enough blood during exercise, which causes the chest pressure you feel.”

“The good news is that the medicines we use can actually stabilize these plaques and prevent them from causing a heart attack. The statin shrinks the soft, dangerous part of the plaque and makes it more stable. The aspirin keeps your blood from clotting on the plaque. That’s why taking these medicines every day is so important—they’re protecting you even when you feel fine.”

“Think of it like maintaining a car: you can’t undo all the wear, but with the right care, you can keep it running safely for a long time.”

Clinical presentation#

Characteristic symptoms#

Classic stable angina:

• Substernal pressure, tightness, or heaviness (rarely sharp or stabbing)
• Precipitated by exertion, emotional stress, cold exposure, or heavy meals
• Relieved within 1-5 minutes by rest or sublingual NTG
• Duration typically 2-10 minutes (not seconds, not >20 minutes)
• Radiation to left arm, jaw, neck, or back (not always present)

Angina equivalents (especially in elderly, women, diabetics):

• Exertional dyspnea without chest discomfort
• Exertional fatigue or weakness
• Nausea or diaphoresis with exertion

CCS classification (Canadian Cardiovascular Society):

• Class I: Angina only with strenuous exertion; ordinary activity does not cause angina
• Class II: Slight limitation; angina with walking >2 blocks or climbing >1 flight of stairs
• Class III: Marked limitation; angina with walking 1-2 blocks or climbing 1 flight
• Class IV: Angina with any physical activity or at rest

Physical exam findings#

• Often normal between episodes
• During ischemia: S4 gallop, transient MR murmur, paradoxical S2 splitting
• Signs of risk factors: xanthelasma, arcus corneae, carotid bruits, diminished peripheral pulses
• Signs of HF if ischemic cardiomyopathy: JVD, S3, peripheral edema, rales

Red flags#

Unstable features requiring ED evaluation:

• New-onset angina (within past 2 months)
• Crescendo pattern: increasing frequency, severity, or duration
• Angina at rest or with minimal exertion
• Angina lasting >20 minutes
• Angina not relieved by NTG
• Associated dyspnea, diaphoresis, syncope, or hypotension
• New ECG changes

Diagnostic workup#

Initial evaluation#

All patients with suspected or known CAD:

• ECG: May be normal; look for Q waves (prior MI), ST-T changes, LVH, arrhythmia. Compare to prior.
• Lipid panel: Total cholesterol, LDL, HDL, triglycerides. Target LDL <70 mg/dL (or <55 if very high risk).
• BMP: Baseline Cr/K before ACE-I; identify CKD (affects prognosis and dosing).
• CBC: Anemia worsens angina; identify and treat.
• A1c or fasting glucose: Diabetes is CAD equivalent; screen all CAD patients.
• TSH: Thyroid disease affects CV risk and can worsen angina.

Assess LV function:

• Echocardiogram: All patients with new CAD diagnosis or change in symptoms. Assess EF, wall motion abnormalities, valvular disease.
• EF <40% significantly changes management (ICD evaluation, HF medications).

Confirmatory testing#

Stress testing for ischemia detection:

Coronary CT angiography (CCTA):

• Best for: intermediate pretest probability, need to rule out CAD, younger patients
• Provides anatomic assessment: stenosis severity, plaque burden, calcium score
• Limitations: less useful if extensive calcification, prior stents, arrhythmia
• Radiation: ~3-5 mSv (less than nuclear stress)

Pretest probability assessment (per 2021 ACC/AHA):

• Low (<15%): Clinical reassurance; no testing needed
• Intermediate (15-65%): Stress testing or CCTA appropriate
• High (>65%): May proceed directly to invasive angiography if revascularization likely

When to refer for specialist workup#

Cardiology referral for invasive angiography:

• High-risk stress test findings:
  • ≥10% ischemic myocardium on imaging
  • EF drop with exercise
  • Exercise-induced hypotension
  • Sustained VT with exercise
  • ST depression ≥2mm or in multiple leads
• Refractory symptoms despite optimal medical therapy
• Reduced EF (<40%) with suspected ischemic etiology
• Uncertain diagnosis after non-invasive testing
• Need for revascularization assessment

What NOT to order#

• Routine coronary calcium score in known CAD: Already have diagnosis; doesn’t change management
• Stress testing within 2 years if stable: Repeat only if symptoms change
• CCTA after prior CABG: Difficult to assess grafts; prefer stress imaging or invasive angio
• Serial troponins in stable angina: Reserve for suspected ACS
• Routine Holter in stable CAD without arrhythmia symptoms: Low yield
• Carotid ultrasound without symptoms: CAD diagnosis already establishes high CV risk

Treatment#

Goals of therapy#

1. Reduce cardiovascular events: Target LDL <70 mg/dL (or <55 if very high risk), BP <130/80, A1c <7% (individualized)
2. Control symptoms: Reduce angina frequency to CCS Class I-II; improve exercise tolerance
3. Preserve LV function: Prevent ischemic cardiomyopathy progression
4. Improve quality of life: Enable return to normal activities

Non-pharmacologic management#

Smoking cessation (most impactful modifiable risk factor):

• Reduces CV mortality by 36% within 2-3 years of quitting
• Offer pharmacotherapy: varenicline (most effective), bupropion, NRT
• Refer to smoking cessation program; set quit date

Diet:

• Mediterranean diet: reduces CV events by ~30% (PREDIMED trial)
• Specific guidance: olive oil as primary fat, fish 2x/week, nuts daily, limit red meat to 1-2x/week, abundant vegetables/fruits
• Sodium <2300 mg/day (or <1500 if HTN)
• Limit added sugars and processed foods

Exercise:

• Target: 150 min/week moderate-intensity aerobic activity (brisk walking, cycling)
• Cardiac rehab referral for all CAD patients: improves outcomes, reduces mortality by 20-25%
• Start low, progress gradually; avoid isometric exercises initially
• Patients can exercise to just below angina threshold

Weight management:

• Target BMI <25 kg/m²; even 5-10% weight loss improves CV risk factors
• Address as part of comprehensive lifestyle intervention

Stress management:

• Chronic stress and depression worsen CV outcomes
• Screen for depression (PHQ-9); treat if present
• Consider referral for stress reduction programs

Pharmacologic management#

Antianginal therapy:

Secondary prevention (all stable CAD patients):

If LDL remains >70 despite max statin + ezetimibe:

• PCSK9 inhibitor (evolocumab 140mg q2wk or alirocumab 75-150mg q2wk): lowers LDL 50-60%
• Requires prior authorization; typically cardiology initiates
• NNT ~50 over 3 years for MACE reduction

Patient counseling points#

For antianginal medications:

• “Beta-blockers slow your heart rate and reduce how hard your heart works. You may feel tired initially—this usually improves in 1-2 weeks. Don’t stop suddenly; we need to taper.”
• “Nitroglycerin is your rescue medicine. Keep it with you always. Sit down before using it—it can make you dizzy. If three doses don’t help, call 911.”
• “The long-acting nitrate prevents angina but can cause headaches at first. Take it in the morning so you have a break overnight—this prevents your body from getting used to it.”

For secondary prevention:

• “The statin is one of the most important medicines you take. It doesn’t just lower cholesterol—it stabilizes the plaques in your arteries and prevents heart attacks. The benefit is proven even if your cholesterol numbers look okay.”
• “Aspirin keeps your blood from clotting on the plaques. Take it every day, even when you feel fine. If you need to stop for surgery, ask your doctor first.”
• “These medicines work together as a team. Skipping doses increases your risk of a heart attack.”

For lifestyle:

• “Quitting smoking is the single best thing you can do for your heart—it cuts your risk of dying from heart disease by more than a third.”
• “Exercise is medicine. Cardiac rehab is like physical therapy for your heart—it’s proven to help you live longer and feel better.”

Monitoring and follow-up#

Initial phase (first 3-6 months):

• Follow-up 2-4 weeks after starting/changing medications
• Assess symptom control (angina frequency, CCS class)
• Check BP, HR at each visit
• BMP at 1-2 weeks after starting ACE-I/ARB
• Lipid panel at 4-12 weeks after starting/changing statin

Stable phase:

• Follow-up every 3-6 months
• Annual: lipid panel, A1c, BMP, CBC
• Echo: repeat if symptoms change or new HF symptoms
• Stress testing: only if symptoms change (not routine surveillance)

Patient education#

What is this condition?#

Your heart has tubes called arteries that bring it blood. In heart disease, fat builds up in these tubes. This makes them narrow. When you move around, your heart needs more blood. If the tubes are too narrow, your heart can’t get enough. This causes chest pain or pressure.

What you can do#

Take your pills every day, even when you feel fine. They protect your heart. If you smoke, stop. This is the best thing you can do. Eat fish, fruits, and greens. Walk most days. Start slow and build up. Keep your rescue pill with you. Sit down before you take it.

When to seek care#

Call your doctor if chest pain happens more often. Call if you need your rescue pill more than before. Call 911 if chest pain lasts more than 15 minutes. Call 911 if your rescue pill does not help after 3 tries. Call 911 if you have chest pain with sweating or feel very sick.

Questions to ask your doctor#

• Is my bad fat level at goal?
• Am I on all the right pills?
• What can I do to stay active?
• When should I use my rescue pill?
• Do I need more tests?

Prognosis and monitoring#

Expected course#

With optimal medical therapy:

• Annual mortality: 1-3% for stable CAD with preserved EF
• Annual MI rate: 1-2%
• Most patients achieve good symptom control
• Quality of life can be excellent with adherence to treatment

Without treatment:

• Higher rates of MI, HF progression, and death
• Symptoms typically worsen over time
• Plaque progression and instability

Factors associated with worse prognosis:

• Reduced EF (<40%)
• Extensive CAD (left main, 3-vessel disease)
• Diabetes
• CKD
• Continued smoking
• Poor medication adherence

Monitoring parameters#

Complications to watch for#

Acute coronary syndrome:

• Plaque rupture → thrombosis → STEMI/NSTEMI
• Watch for: change in angina pattern, rest pain, prolonged symptoms
• Prevention: adherence to secondary prevention medications

Heart failure:

• Ischemic cardiomyopathy from repeated ischemia or prior MI
• Watch for: dyspnea, edema, orthopnea, weight gain
• Prevention: revascularization if indicated, optimal medical therapy

Arrhythmias:

• Scar from prior MI can cause VT
• Ischemia can trigger AF
• Watch for: palpitations, syncope, near-syncope

Special populations#

Elderly/geriatric#

Treatment considerations:

• More likely to have atypical symptoms (dyspnea, fatigue rather than chest pain)
• Higher bleeding risk with aspirin—still indicated but monitor closely
• Beta-blockers: start lower doses (metoprolol 12.5-25mg); more sensitive to bradycardia and hypotension
• Statins: continue in secondary prevention regardless of age; benefit persists in elderly
• Nitrates: higher risk of hypotension and falls; start with lower doses

Beers criteria considerations:

• Avoid short-acting nifedipine (hypotension, reflex tachycardia)
• Use caution with nitrates (orthostatic hypotension, fall risk)
• Aspirin for primary prevention not recommended >70 years, but secondary prevention still indicated

BP targets:

• May accept SBP <140 rather than <130 if frail or orthostatic symptoms
• Avoid aggressive lowering that causes dizziness or falls

Chronic kidney disease#

Medication adjustments:

Special considerations:

• CKD is CAD equivalent—aggressive secondary prevention indicated
• Higher CV mortality in CKD; statins still beneficial
• Monitor K closely with ACE-I/ARB (higher hyperkalemia risk)
• Contrast nephropathy risk with angiography—ensure hydration, hold metformin

Other populations#

Diabetes:

• CAD often more extensive and diffuse
• Consider SGLT2 inhibitor (empagliflozin, dapagliflozin) for CV benefit even without HF
• GLP-1 RA (semaglutide, liraglutide) reduces CV events
• Tighter LDL goal (<55 mg/dL) per ESC guidelines

Women:

• More likely to have microvascular disease (angina with non-obstructive CAD)
• Atypical presentations more common
• Same secondary prevention applies
• Pregnancy: avoid statins, ACE-I/ARB; use beta-blockers cautiously

Patients on anticoagulation (AF, VTE):

• Generally avoid adding aspirin to DOAC/warfarin (bleeding risk outweighs benefit)
• Exception: first 1-12 months post-PCI may need dual or triple therapy—cardiology decision
• If on warfarin + aspirin, target INR 2.0-2.5 (lower range)

Polypharmacy considerations:

• Statin interactions: avoid simvastatin >20mg with diltiazem, verapamil, amiodarone
• Ranolazine: avoid with strong CYP3A inhibitors (ketoconazole, clarithromycin)
• Colchicine: reduce dose or avoid with CYP3A inhibitors
• NSAIDs: avoid if possible (increase CV events, reduce aspirin efficacy, worsen HTN)

When to refer#

Specialist referral criteria#

Cardiology referral (routine, 2-4 weeks):

• New diagnosis of CAD for risk stratification and stress testing
• Stable symptoms requiring optimization of antianginal therapy
• Need for stress testing interpretation
• LDL not at goal despite max statin + ezetimibe (PCSK9 inhibitor evaluation)
• Consideration for cardiac rehab referral

Cardiology referral (urgent, within 1 week):

• Worsening angina despite medical therapy
• New-onset angina
• Angina at low exertion levels (CCS Class III-IV)
• High-risk stress test results
• New reduction in EF
• Syncope or near-syncope with exertion

Interventional cardiology/cardiac surgery:

• Refractory symptoms despite optimal medical therapy
• High-risk anatomy on non-invasive testing
• Need for revascularization assessment

Urgency levels#

Smartphrase snippets#

Stable CAD, well-controlled: CAD with stable angina, CCS Class I-II. On aspirin, high-intensity statin (LDL at goal), beta-blocker. No rest pain, exercise tolerance unchanged. Continue current regimen, follow-up 6 months.

Stable CAD, suboptimal control: CAD with angina 2-3x/week, CCS Class II-III. LDL above goal. Increasing beta-blocker, adding CCB and ezetimibe. Recheck lipids 6 weeks, cardiology referral if symptoms persist.

New diagnosis CAD: New CAD diagnosis per positive stress test, EF preserved. Started aspirin, statin, beta-blocker. Cardiology and cardiac rehab referrals placed, follow-up 2-4 weeks.

Related pages#

• Chest Pain (complaint) — symptom-based approach to chest pain differential and initial risk stratification
• Palpitations (complaint) — evaluation of arrhythmia symptoms that may occur with CAD
• Dyspnea on Exertion (complaint) — cardiac vs pulmonary causes of exertional dyspnea
• Heart Failure (problem) — management of ischemic cardiomyopathy, HFrEF/HFpEF, GDMT optimization
• Hypertension (problem) — BP management for CV risk reduction
• Hyperlipidemia (problem) — statin therapy, LDL targets, and secondary prevention
• Atrial Fibrillation (problem) — common comorbidity in CAD patients